Inaugural operating profit fails to lift 111 Inc.
The drug distributor expects to benefit from an ongoing crackdown on corruption in its industry due to the company’s focus on distribution to pharmacies rather than hospitals Key Takeaways: 111…
Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.
Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87%…
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
- Jiuyuan Gene seeks IPO cash for bet on weight-loss drugs
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
